DDInter1570 DDInter621
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy.
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Ranolazine {u} (Compound) resembles {v} (Compound) Guaifenesin
Guaifenesin {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Lorlatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Ranolazine {u} (Compound) resembles {v} (Compound) Eprazinone
Eprazinone {u} (Compound) resembles {v} (Compound) Bepridil
Bepridil {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Ranolazine {u} (Compound) resembles {v} (Compound) Propranolol
Propranolol {u} (Compound) resembles {v} (Compound) Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Venetoclax {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Iloprost
Iloprost {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Fedratinib {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Fluoxetine
Fluoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may lead to a major life threatening interaction when taken with Edoxaban
Ranolazine (Compound) resembles Guaifenesin (Compound) and Guaifenesin (Compound) resembles Carvedilol (Compound) and Carvedilol may lead to a major life threatening interaction when taken with Edoxaban
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Ranolazine (Compound) resembles Eprazinone (Compound) and Eprazinone (Compound) resembles Bepridil (Compound) and Bepridil may lead to a major life threatening interaction when taken with Edoxaban
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Ranolazine (Compound) resembles Propranolol (Compound) and Propranolol (Compound) resembles Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may lead to a major life threatening interaction when taken with Edoxaban
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Edoxaban
Ranolazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fluoxetine (Compound) and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban